Project Grant FF203K094249

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $601,340 to Transchromix LLC to develop a novel therapeutic intervention for early-stage type 1 diabetes (T1D). The research aims to target a translational regulatory mechanism involving the G9A histone methyltransferase, which was found to specifically suppress the pathogenicity of...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $851,200 to The Medical College of Wisconsin, Inc. to investigate the role of the PTPN22 gene in regulating the balance between IL-21+ CD4 T cells and FOXP3+ regulatory T cells in the development of type 1 diabetes (T1D). The research aims to determine if the PTPN22 619W risk allele alters this balance, and to...

This federal Cooperative Agreement award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to develop advanced pancreatic-immune organoid models to study type 1 diabetes (T1D) subtypes and therapeutic responses. The $1,201,988 award to Yale University will fund research to characterize and analyze pancreatic organoids derived from induced pluripotent stem cells...

The U01CA294062 Cooperative Agreement award, funded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), is providing $558,775 to Brigham & Women's Hospital Inc. from August 1, 2024 to July 31, 2029. The project aims to overcome the limitations of BET inhibition in NUT carcinoma (NC), an aggressive form of cancer, by identifying targetable mechanisms of gene regulation that maintain NC growth. The research uses a two-pronged approach,...

The National Cancer Institute (NCI) awarded Nerx Biosciences Inc., a small disadvantaged business, a $1,078,680 Project Grant under the Cancer Treatment Research (CFDA 93.395) program. The funding will support the development and characterization of a novel small molecule inhibitor, NERX-329, which targets the DNA damage response sensor Replication Protein A (RPA). This first-in-class cancer therapy aims to disrupt the RPA-DNA interaction, inducing a state of "chemical RPA...

This SBIR Phase I project, awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), aims to develop a method to turn on cancer immunotherapies only at the site of disease. The $275,000 award will support Synsorybio, Inc., a for-profit organization, in creating protein switches that activate immunotherapies in response to disease signals, rather than indiscriminately throughout the body. This approach seeks to improve the...

This $398,728 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports the development of a novel homologous recombination (HR) inhibitor, CP-8, to sensitize triple-negative breast cancer (TNBC) cells to DNA-damaging agents. The project aims to examine the synergy of CP-8 with various DNA-damaging therapies, including PARP inhibitors and ionizing radiation, in TNBC cell lines, patient-derived xenograft models, and in vivo...

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $1,207,770 Cooperative Agreement grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to The Trustees of Columbia University in the City of New York, doing business as the Health Sciences Division. The funding will support a project titled "Understanding Thymic Epithelial and Hematopoietic Stem Cell-Intrinsic Immune Abnormalities Driving T1D in Optimized HIS...

This federal Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $1,418,424 to Tigatx Inc., a small business in Boston, Massachusetts, to advance the late-stage development and de-risking of a novel monoclonal antibody immunotherapy called TIGA-001 for the treatment of EGFR-positive solid cancers, with a focus on non-small cell lung cancer. The funding supports critical product development activities including CMC work, in vitro...

This $274,991 Phase I Small Business Innovation Research (SBIR) award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development of a new approach to deliver cancer-killing proteins specifically to acute myeloid leukemia (AML) cells while sparing healthy cells. The project aims to engineer natural killer (NK) cells with targeted protein degraders (TPDs) against three common AML driver proteins, with the goal of demonstrating...